Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling

Sir James Black developed β-blockers, one of the most useful groups of drugs in use today. Not only are they being used for their original purpose to treat angina and cardiac arrhythmias, but they are also effective therapeutics for hypertension, cardiac failure, glaucoma, migraine and anxiety. Rece...

Full description

Bibliographic Details
Main Authors: Baker, Jillian G., Hill, Stephen J., Summers, Roger J.
Format: Article
Published: Elsevier 2011
Online Access:https://eprints.nottingham.ac.uk/2796/
_version_ 1848790877840867328
author Baker, Jillian G.
Hill, Stephen J.
Summers, Roger J.
author_facet Baker, Jillian G.
Hill, Stephen J.
Summers, Roger J.
author_sort Baker, Jillian G.
building Nottingham Research Data Repository
collection Online Access
description Sir James Black developed β-blockers, one of the most useful groups of drugs in use today. Not only are they being used for their original purpose to treat angina and cardiac arrhythmias, but they are also effective therapeutics for hypertension, cardiac failure, glaucoma, migraine and anxiety. Recent studies suggest that they might also prove useful in diseases as diverse as osteoporosis, cancer and malaria. They have also provided some of the most useful tools for pharmacological research that have underpinned the development of concepts such as receptor subtype selectivity, agonism and inverse agonism, and ligand-directed signalling bias. This article examines how β-blockers have evolved and indicates how they might be used in the future.
first_indexed 2025-11-14T18:19:36Z
format Article
id nottingham-2796
institution University of Nottingham Malaysia Campus
institution_category Local University
last_indexed 2025-11-14T18:19:36Z
publishDate 2011
publisher Elsevier
recordtype eprints
repository_type Digital Repository
spelling nottingham-27962020-05-04T20:23:22Z https://eprints.nottingham.ac.uk/2796/ Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling Baker, Jillian G. Hill, Stephen J. Summers, Roger J. Sir James Black developed β-blockers, one of the most useful groups of drugs in use today. Not only are they being used for their original purpose to treat angina and cardiac arrhythmias, but they are also effective therapeutics for hypertension, cardiac failure, glaucoma, migraine and anxiety. Recent studies suggest that they might also prove useful in diseases as diverse as osteoporosis, cancer and malaria. They have also provided some of the most useful tools for pharmacological research that have underpinned the development of concepts such as receptor subtype selectivity, agonism and inverse agonism, and ligand-directed signalling bias. This article examines how β-blockers have evolved and indicates how they might be used in the future. Elsevier 2011-04 Article PeerReviewed Baker, Jillian G., Hill, Stephen J. and Summers, Roger J. (2011) Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling. Trends in Pharmacological Sciences, 32 (4). pp. 227-234. ISSN 0165-6147 http://www.sciencedirect.com/science/article/pii/S0165614711000320 doi:10.1016/j.tips.2011.02.010 doi:10.1016/j.tips.2011.02.010
spellingShingle Baker, Jillian G.
Hill, Stephen J.
Summers, Roger J.
Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling
title Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling
title_full Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling
title_fullStr Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling
title_full_unstemmed Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling
title_short Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling
title_sort evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling
url https://eprints.nottingham.ac.uk/2796/
https://eprints.nottingham.ac.uk/2796/
https://eprints.nottingham.ac.uk/2796/